9. Burgess SC, Basaran BH, Davison TF (2001) Resistance to Marek’s disease
herpesvirus-induced lymphoma is multiphasic and dependent on host genotype.
Vet Pathol 38: 129–142.
10. Burgess SC, Davison TF (2002) Identification of the neoplastically transformed
cells in Marek’s disease herpesvirus-induced lymphomas: recognition by the
monoclonal antibody AV37. J Virol 76: 7276–7292.
11. Nazerian K, Sharma JM (1975) Detection of T-cell surface antigens in a Marek’s
disease lymphoblastoid cell line. J Natl Cancer Inst 54: 277–279.
12. Parcells MS, Dienglewicz RL, Anderson AS, Morgan RW (1999) Recombinant
Marek’s disease virus (MDV)-derived lymphoblastoid cell lines: regulation of a
marker gene within the context of the MDV genome. J Virol 73: 1362–1373.
13. Schat KA, Chen CL, Calnek BW, Char D (1991) Transformation of T-
lymphocyte subsets by Marek’s disease herpesvirus. J Virol 65: 1408–1413.
14. Schat KA, Chen CL, Shek WR, Calnek BW (1982) Surface antigens on Marek’s
disease lymphoblastoid tumor cell lines. J Natl Cancer Inst 69: 715–720.
15. Brown AC, Baigent SJ, Smith LP, Chattoo JP, Petherbridge LJ, et al. (2006)
Interaction of MEQ protein and C-terminal-binding protein is critical for
induction of lymphomas by Marek’s disease virus. Proc Natl Acad Sci U S A
16. Ross N, O’Sullivan G, Rothwell C, Smith G, Burgess SC, et al. (1997) Marek’s
disease virus EcoRI-Q gene (meq) and a small RNA antisense to ICP4 are
abundantly expressed in CD4+ cells and cells carrying a novel lymphoid marker,
AV37, in Marek’s disease lymphomas. J Gen Virol 78(Pt 9): 2191–2198.
17. Xie Q , Anderson AS, Morgan RW (1996) Marek’s disease virus (MDV) ICP4,
pp38, and meq genes are involved in the maintenance of transformation of
MDCC-MSB1 MDV-transformed lymphoblastoid cells. J Virol 70: 1125–1131.
18. Delecluse HJ, Hammerschmidt W (1993) Status of Marek’s disease virus in
established lymphoma cell lines: herpesvirus integration is common. J Virol 67:
19. Delecluse HJ, Schuller S, Hammerschmidt W (1993) Latent Marek’s disease
virus can be activated from its chromosomally integrated state in herpesvirus-
transformed lymphoma cells. EMBO J 12: 3277–3286.
20. Bublot MaSJ (2004) Vaccination against Marek’s disease. In: Davison TF,
Nair V, eds . Marek’s disease An evolving Problem. London: Elsevier Academic
Press. pp 168–182.
21. Davison F, Nair V (2005) Use of Marek’s disease vaccines: could they be driving
the virus to increasing virulence? Expert Rev Vaccines 4: 77–88.
22. Witter RL (1998) Control strategies for Marek’s disease: a perspective for the
future. Poult Sci 77: 1197–1203.
23. Morimura T, Ohashi K, Sugimoto C, Onuma M (1998) Pathogenesis of Marek’s
disease (MD) and possible mechanisms of immunity induced by MD vaccine.
J Vet Med Sci 60: 1–8.
24. Wu C, Gan J, Jin Q, Chen C, Liang P, et al. (2009) Revaccination with Marek’s
disease vaccines induces productive infection and superior immunity. Clin
Vaccine Immunol 16: 184–193.
25. Bacon LD, Crittenden LB, Witter RL, Fadly A, Motta J (1983) B5 and B15
associated with progressive Marek’s disease, Rous sarcoma, and avian leukosis
virus-induced tumors in inbred 15I4 chickens. Poult Sci 62: 573–578.
26. Bacon LD, Witter RL (1993) Influence of B-haplotype on the relative efficacy of
Marek’s disease vaccines of different serotypes. Avian Dis 37: 53–59.
27. Bacon LD, Witter RL (1994) B haplotype influence on the relative efficacy of
Marek’s disease vaccines in commercial chickens. Poult Sci 73: 481–487.
28. Bacon LD, Witter RL, Crittenden LB, Fadly A, Motta J (1981) B-haplotype
influence on Marek’s disease, Rous sarcoma, and lymphoid leukosis virus-
induced tumors in chickens. Poult Sci 60: 1132–1139.
29. Briles WE, Briles RW, Taffs RE, Stone HA (1983) Resistance to a malignant
lymphoma in chickens is mapped to subregion of major histocompatibility (B)
complex. Science 219: 977–979.
30. Buscaglia C, Calnek BW (1988) Maintenance of Marek’s disease herpesvirus
latency in vitro by a factor found in conditioned medium. J Gen Virol 69(Pt 11):
31. Kaiser P, Underwood G, Davison F (2003) Differential cytokine responses
following Marek’s disease virus infectio n of chickens differing in resistance to
Marek’s disease. J Virol 77: 762–768.
32. Levy AM, Heller ED, Leitner G, Davidson I (1999) Effect of native chicken
interferon on MDV replication. Acta Virol 43: 121–127.
33. Volpini LM, Calnek BW, Sekellick MJ, Marcus PI (1995) Stages of Marek’s
disease virus latency defined by variable sensitivity to interferon modulation of
viral antigen expression. Vet Microbiol 47: 99–109.
34. Xing Z, Schat KA (2000) Expression of cytokine genes in Marek’s disease virus-
infected chickens and chicken embryo fibroblast cultures. Immunology 100:
35. Schat KA (1991) Importance of cell-mediated immunity in Marek’s disease and
other viral tumor diseases. Poult Sci 70: 1165–1175.
36. Schat KA, Markowski-Grimsrud CJ (2001) Immune responses to Marek’s
disease virus infection. Curr Top Microbiol Immunol 255: 91–120.
37. Markowski-Grimsrud CJ, Schat KA (2002) Cytotoxic T lymphocyte responses to
Marek’s disease herpesvirus-encoded glycoproteins. Vet Immunol Immuno-
pathol 90: 133–144.
38. Omar AR, Schat KA (1996) Syngeneic Marek’s disease virus (MDV)-specific
cell-mediated immune responses against immediate early, late, and unique
MDV proteins. Virology 222: 87–99.
39. Omar AR, Schat KA (1997) Characteriza tion of Marek’s disease herpesvirus-
specific cytotoxic T lymphocytes in chickens inoculated with a non-oncogenic
vaccine strain of MDV. Immunology 90: 579–585.
40. Morimura T, Cho KO, Kudo Y, Hiramoto Y, Ohashi K, et al. (1999) Anti-viral
and anti-tumor effects induced by an attenuated Marek’s disease virus in CD4-
or CD8-deficient chickens. Arch Virol 144: 1809–1818.
41. Day EK, Carmichael AJ, ten Berge IJ, Waller EC, Sissons JG, et al. (200 7)
Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into
memory following primary infection with a persistent human virus: human
cytomegalovirus. J Immunol 179: 3203–3213.
42. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, et al. (2005)
Repertoire, diversity, and differentiation of specific CD8 T cells are associated
with immune protection against human cytomegalovirus disease. J Exp Med
43. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, et al. (1998) Direct
visualization of antigen-specific CD8+ T cells during the primary immune
response to Epstein-Barr virus In vivo. J Exp Med 187: 1395–1402.
44. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, et al. (2007) A
T cell immune evasion protein specific to Epstein-Barr virus and its close
relatives in Old World primates. J Exp Med 204: 1863–1873.
45. Mwangi WN, Beal RK, Powers C, Wu X, Humphrey T, et al. (2010) Regional
and global changes in TCRalphabeta T cell repertoires in the gut are dependent
upon the complexity of the enteric microflora. Dev Comp Immunol 34:
46. Cooper MD, Chen CL, Bucy RP, Thompson CB (1991) Avian T cell ontogeny.
Adv Immunol 50: 87–117.
47. McCormack WT, Tjoelker LW, Stella G, Postema CE, Thompson CB (1991)
Chicken T-cell receptor beta-chain diversity: an evolutionarily conserved D
beta-encoded glycine turn within the hypervariable CDR3 domain. Proc Natl
Acad Sci U S A 88: 7699–7703.
48. Shigeta A, Sato M, Kawashima T, Horiuchi H, Matsuda H, et al. (2004)
Genomic organization of the chicken T-cell receptor beta chain D-J-C region.
J Vet Med Sci 66: 1509–1515.
49. Tjoelker LW, Carlson LM, Lee K, Lahti J, McCormack WT, et al. (1990)
Evolutionary conservation of antigen recognition: the chicken T-cell receptor
beta chain. Proc Natl Acad Sci U S A 87: 7856–7860.
50. Schat KA, Calnek BW, Fabricant J (1982) Characterisation of two highly
oncogenic strains of Marek’s disease virus. Avian Pathol 11: 593–605.
51. Petherbridge L, Brown AC, Baigent SJ, Howes K, Sacco MA, et al. (2004)
Oncogenicity of virulent Marek’s disease virus cloned as bacterial artificial
chromosomes. J Virol 78: 13376–13380.
52. Petherbridge L, Howes K, Baigent SJ, Sacco MA, Evans S, et al. (2003)
Replication-competent bacterial artificial chromosomes of Marek’s disease virus:
novel tools for generation of molecularly defined herpesvirus vaccines. J Virol
53. Chan MM, Chen CL, Ager LL, Cooper MD (1988) Identification of the avian
homologues of mammalian CD4 and CD8 antigens. J Immunol 140:
54. Akiyama Y, Kato S (1974) Scanning electron microscopy of lymphoid cell lines
and lymphocytes from thymus, bursa and blood of chickens. Biken J 17:
55. Nazerian K, Witter RL (1975) Properties of a chicken lymphoblastoid cell line
from Marek’s disease tumor. J Natl Cancer Inst 54: 453–458.
56. Payne LN, Howes K, Rennie M, Bumstead JM, Kidd AW (1981) Use of an agar
culture technique for establishing lymphoid cell lines from Marek’s disease
lymphomas. Int J Cancer 28: 757–766.
57. Nazerian K, Steph ens EA, Sharma JM, Lee LF, Gailitis M, et al. (1977) A
nonproducer T lymph oblastoid cell line from Marek’s disease transplantable
tumor (JMV). Avian Dis 21: 69–76.
58. Yao Y, Zhao Y, Smith LP, Lawrie CH, Saunders NJ, et al. (2009) Differential
expression of microRNAs in Marek’s disease virus-transformed T-lymphoma cell
lines. J Gen Virol 90: 1551–1559.
59. Yao Y, Zhao Y, Xu H, Smith LP, Lawrie CH, et al. (2008) MicroRNA profile of
Marek’s disease virus-transformed T-cell line MSB-1: predominance of virus-
encoded microRNAs. J Virol 82: 4007–4015.
60. Dunon D, Schwager J, Dangy JP, Cooper MD, Imhof BA (1994) T cell
migration during development: homing is not related to TCR V beta 1
repertoire selection. EMBO J 13: 808–815.
61. Agresti A, Coull B (1998) Approximate is better than ’exact’ for interval
estimation of binomial proportions. Am Stat 52: 119–126.
62. Nazerian K (1987) An updated list of avian cell lines and transplantable tumours.
Avian Pathol 16: 527–544.
63. Parvizi P, Read LR, Abdul-Careem MF, Sarson AJ, Lusty C, et al. (2009)
Cytokine gene expression in splenic CD4+ and CD8+ T cell subsets of
genetically resistant and susceptible chickens infected with Marek’s disease virus.
Vet Immunol Immunopathol 132: 209–217.
64. Callan MF, Annels N, Steven N, Tan L, Wilson J, et al. (1998) T cell selection
during the evolution of CD8+ T cell memory in vivo. Eur J Immunol 28:
65. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral
infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:
66. Collette A, Cazenave PA, Pied S, Six A (2003) New methods and software tools
for high throughput CDR3 spectratyping. Application to T lymphocyte
TCR Repertoire Analysis during Infection with MDV
PLoS Pathogens | www.plospathogens.org 17 May 2011 | Volume 7 | Issue 5 | e1001337